Skip to main content
Fanli Digital Technology Co., Ltd logo

Fanli Digital Technology Co., Ltd — Investor Relations & Filings

Ticker · 600228 ISIN · CNE000000Y78 Shanghai Stock Exchange Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 2,251 across all filing types
Latest filing 2020-03-18 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600228

About Fanli Digital Technology Co., Ltd

https://corp.fanli.com/

Fanli Digital Technology Co., Ltd. provides e-commerce integration and digital marketing services. The company operates a comprehensive platform that connects consumers with various online retail ecosystems through value-added services such as cash-back rewards, discount coupons, and promotional insights. Its core business model focuses on performance-based marketing, utilizing data-driven strategies to facilitate sales conversions for brand partners. Key offerings include brand promotion, user loyalty management, and targeted advertising solutions. By integrating diverse shopping channels into a single interface, the company optimizes the consumer purchasing journey and provides brands with scalable traffic acquisition tools. The platform serves as a strategic intermediary, leveraging user behavioral data to enhance marketing efficiency and provide measurable returns for merchants while delivering cost savings to a broad user base.

Recent filings

Filing Released Lang Actions
华泰联合证券关于ST昌九重大资产置换、发行股份及支付现金购买资产并募集配套资金暨关联交易预案的独立财务顾问核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed independent financial advisor's verification opinion related to a major asset swap, issuance of shares, cash payment for asset purchase, and fundraising plan involving Jiangxi Changjiu Biochemical Co., Ltd. It includes detailed descriptions of the transaction structure, pricing, share issuance, lock-up periods, and regulatory approvals required. The document references compliance with Chinese securities regulations and includes extensive financial and legal details about the restructuring transaction. This type of document is typical of a financial advisory report related to a major asset restructuring and capital raising transaction, which is part of a merger or acquisition process. It is not a simple announcement or a brief summary but a comprehensive advisory opinion. Therefore, the most appropriate classification is "Capital/Financing Update (CAP)" as it deals with fundraising, issuance of shares, and capital structure changes related to a major asset restructuring transaction.
2020-03-18 Chinese
华泰联合证券有限责任公司关于江西昌九生物化工股份有限公司股票价格波动未达到《关于规范上市公司信息披露及相关各方行为的通知》第五条相关标准的核查意见
Regulatory Filings Classification · 95% confidence The document is a verification opinion from an independent financial advisor (华泰联合证券有限责任公司) regarding the stock price fluctuation of 江西昌九生物化工股份有限公司 in relation to regulatory standards under the China Securities Regulatory Commission's notice. It discusses stock price movements before a major asset restructuring transaction and concludes that the price fluctuations do not constitute abnormal volatility. The document is short (1178 characters), contains no financial statements or detailed financial data, and is essentially a regulatory compliance opinion related to a transaction. It is not an annual report, audit report, earnings release, or other financial report. It is also not a simple announcement of a report publication. The content fits best under Regulatory Filings (RNS), as it is a regulatory compliance document that does not fit other specific categories.
2020-03-18 Chinese
独立董事关于第七届董事会第十二次会议相关议案的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on proposals related to a major asset restructuring involving asset swaps, share issuance, and cash payments to acquire another company. It discusses compliance with laws, regulations, and internal governance, and confirms the fairness and legality of the transaction. The document is not a full financial report but rather a formal opinion and approval related to board meeting proposals on a major transaction. It does not contain financial statements or detailed financial data but focuses on governance and transaction approval. This fits best under Board/Management Information (MANG), as it relates to board meeting proposals and approvals concerning a significant corporate transaction.
2020-03-18 Chinese
独立董事关于公司重大资产置换、发行股份及支付现金购买资产并募集配套资金暨关联交易的独立意见
Audit Report / Information Classification · 95% confidence The document is an independent opinion from the independent directors regarding a major asset swap, issuance of shares, cash payment for asset purchase, and related party transactions. It discusses compliance with laws and regulations, the fairness and feasibility of the transaction, and the independence of intermediaries. The document is not a full financial report but an opinion related to a significant corporate transaction and related disclosures. It does not contain financial statements or quarterly/yearly results. It is not a regulatory announcement of voting results or a proxy statement. It is a standalone opinion on a major asset restructuring and related party transaction, which fits best under Audit Report / Information (AR) as it involves independent directors' opinion on the transaction's compliance and fairness, which is typical for such reports in Chinese listed companies. Q1 2020
2020-03-18 Chinese
第七届监事会第十一次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions passed by the Supervisory Board regarding a major asset restructuring involving asset swaps, issuance of shares, cash payments, and fundraising. It includes detailed descriptions of the transaction structure, pricing, lock-up arrangements, performance commitments, and legal compliance. The document repeatedly states that the Supervisory Board could not form resolutions due to conflicts of interest and that the matters will be submitted to the shareholders' meeting for approval. The content focuses on the approval and procedural aspects of a major asset restructuring and related financing, which is characteristic of a Capital/Financing Update. It is not a full annual or interim report, audit report, or earnings release. It is not a simple announcement of voting results but a detailed disclosure of the transaction and related resolutions. Therefore, the document fits best under Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content confirm it is not a mere announcement or regulatory filing. Confidence is high due to the extensive transaction details and repeated references to issuance of shares and fundraising.
2020-03-18 Chinese
华泰联合证券有限责任公司关于江西昌九生物化工股份有限本次重组前12个月内购买、出售资产情况的核查意见
Audit Report / Information Classification · 95% confidence The document is a verification opinion from an independent financial advisor regarding asset purchase and sale activities within 12 months prior to a major asset restructuring transaction. It references the regulatory framework for major asset restructurings and details specific asset transactions, confirming no related asset transactions occurred within the period except for a minor unrelated asset disposal. The document is not a full financial report but a specialized audit or verification report related to a restructuring process. It does not contain comprehensive financial statements or management discussion but focuses on compliance and verification of asset transactions. Therefore, it fits best under Audit Report / Information (AR), which covers standalone audit reports and applied accounting principles related to internal or regulatory checks excluding full annual or interim reports. FY 2019
2020-03-18 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.